Kaletra

Base Information

• Chemical Name: Kaletra
• CAS No.: 369372-47-4
• Molecular Formula: C74H96N10O10S2
• Molecular Weight: 1349.745
• DSSTox Substance ID: DTXSID30190428
• Wikipedia: Lopinavir/ritonavir
• Wikidata: Q3836750
• NCI Thesaurus Code: C2096
• Mol file: 369372-47-4.mol

Synonyms:Aluvia;Kaletra;Lopimune;lopinavir and ritonavir;lopinavir and ritonavir drug combination;lopinavir, ritonavir drug combination;lopinavir-ritonavir drug combination

Chemical Property of Kaletra

Chemical Property:

• Vapor Pressure: 0mmHg at 25°C
• Boiling Point: 947°C at 760 mmHg
• Flash Point: 526.6°C
• Hydrogen Bond Donor Count: 8
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 33
• Exact Mass: 1348.67523164
• Heavy Atom Count: 96
• Complexity: 1980

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
• Isomeric SMILES: CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
• Recent ClinicalTrials: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
• Recent EU Clinical Trials: A Pilot study platform to investigate the pharmacodynamics on QT‐prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers
• Clinical Use: Recently, the U.S. FDA has approved the release of lopinavir/ritonavir combination in patients who have not responded to other regimens for treatment of HIV. The product is available in a soft-gelatin capsule containing 133.3 mg of lopinavir and 33.3 mg of ritonavir as well as in oral solutions containing 80 mg/mL of lopinavir and 20 mg/mL of ritonavir. The small amount of ritonavir is not expected to have antiretroviral activity; rather, the ritonavir is meant to increase the plasma concentrations of lopinavir by inhibiting lopinavir's metabolism by CYP3A4 (ritonavir acts as a booster). These drugs, in combination with other antiretroviral agents, have been approved for use in adults as well as in patients between the ages of 6 months and 12 years. This is the first PI to be indicated for the very young.